4-羟基-7-甲氧基茚满 | 38998-04-8

• 物质功能分类: 有机原料
• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 4-羟基-7-甲氧基茚满
• 英文名称: 7-methoxy-indan-4-ol
• 英文别名: 7-methoxyindan-4-ol；7-Hydroxy-4-methoxy-indan；7-methoxy-2,3-dihydro-1H-inden-4-ol
• CAS: 38998-04-8
• 化学式: C₁₀H₁₂O₂
• mdl: MFCD04038952
• 分子量: 164.204
• InChiKey: MUYRQNYFMUEYKP-UHFFFAOYSA-N

物化性质

• 沸点：
  320.1±42.0 °C(Predicted)
• 密度：
  1.164±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2909499000

反应信息

• 作为反应物：
  描述：

  4-羟基-7-甲氧基茚满 在 potassium carbonate 作用下， 生成 7-methoxy-5-prop-2-enyl-2,3-dihydro-1H-inden-4-ol
  参考文献：
  名称：

  Dallacker,F.; Van Werst,J., Chemische Berichte, 1972, vol. 105, p. 2565 - 2574

  摘要：

  DOI：
• 作为产物：
  描述：

  茚满 在 sodium hydroxide 、 potassium dihydrogenphosphate 、 三氯化铝 、 甲酸 、 sodium dithionite 、 双氧水 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 4-羟基-7-甲氧基茚满
  参考文献：
  名称：

  Dallacker,F.; Van Werst,J., Chemische Berichte, 1972, vol. 105, p. 2565 - 2574

  摘要：

  DOI：

文献信息

• Novel Compounds
  申请人：Chhipa Laxmikant

  公开号：US20100168110A1

  公开（公告）日：2010-07-01

  The present invention discloses a novel thyroid like compounds of formula (I), wherein R 1 R 2 , R 3 , R 4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

  本发明公开了一种新型的甲状腺类似化合物，其化学式为（I），其中R1、R2、R3、R4和Z如规范中所定义，以及其制备方法、含有这种化合物的组合物和这种化合物及组合物作为药物的用途。此外，化合物的化学式（I）具有与甲状腺受体显著低的结合亲和力，因此在很大程度上缺乏甲状腺毒性作用。该发明还涉及将化学式（I）的化合物用于制备用于治疗肥胖、血脂异常、代谢综合征以及与代谢综合征相关的合并症等各种疾病状况的药物。
• Malonamic acids and derivatives thereof as thyroid receptor ligands
  申请人：Chiang P. Yuan-Ching

  公开号：US20070173548A1

  公开（公告）日：2007-07-26

  The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders.

  本发明涉及新型甲状腺受体配体，更具体地涉及公式I的马隆酰胺及其衍生物，其在治疗肥胖、超重、高脂血症、青光眼、心律失常、皮肤疾病、甲状腺疾病、甲状腺功能减退、甲状腺癌和相关疾病如糖尿病、动脉硬化、高血压、冠心病、充血性心力衰竭、高胆固醇血症、抑郁症、骨质疏松和脱发方面具有用途。本发明还提供了治疗上述疾病和疾病的方法、药物组合物和工具包。
• NOVEL COMPOUNDS
  申请人：Chhipa Laxmikant

  公开号：US20120202816A1

  公开（公告）日：2012-08-09

  The present invention discloses a novel thyroid like compounds of formula (I), wherein R 1 R 2 , R 3 , R 4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

  本发明揭示了一种新型的类甲状腺化合物，其化学式为（I），其中R1R2、R3、R4和Z的定义如规范中所述，以及其制备方法、含有该类化合物的组合物以及该类化合物和组合物作为药物的用途。此外，化合物（I）具有显著低的甲状腺受体结合亲和力，因此明显缺乏甲状腺毒性作用。本发明还涉及将化合物（I）用于制备治疗肥胖、血脂异常、代谢综合征和与代谢综合征相关的共病症的药物的用途。
• Thyroid like compounds
  申请人：Torrent Pharmaceuticals Ltd.

  公开号：US08143424B2

  公开（公告）日：2012-03-27

  A novel thyroid like compounds of formula (I), wherein R1, R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition and use thereof. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions including obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

  一种具有式（I）的新型甲状腺类似物，其中R1、R2、R3、R4和Z如规范中所定义，其制备方法、组合物和使用方法。此外，式（I）化合物与甲状腺受体的结合亲和力显著降低，因此极少具有甲状腺毒性作用。本发明还涉及使用式（I）化合物制备药物，用于治疗包括肥胖、血脂异常、代谢综合征以及与代谢综合征相关的共病症等各种疾病条件。
• Pyrazole-based thyroid receptor compounds
  申请人：Chhipa Laxmikant

  公开号：US08378118B2

  公开（公告）日：2013-02-19

  The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

  本发明揭示了一种新颖的甲状腺类似化合物，其化学式为（I），其中R1、R2、R3、R4和Z如规范中所定义，以及其制备方法、含有此类化合物的组合物和将此类化合物和组合物用作药物的用途。此外，化合物（I）对甲状腺受体的结合亲和力显著降低，因此在很大程度上缺乏甲状腺毒性效应。本发明还涉及将化合物（I）用于制备治疗肥胖症、血脂异常、代谢综合征以及与代谢综合征相关的共病症的药物。